Centogene N.V. announced the Company's Supervisory Board's nomination of Kim Stratton as Chief Executive Officer, transitioning from her prior designation as Interim CEO. In her role as CEO, Mrs. Stratton will now lead CENTOGENE's ongoing important strategic evolution on its path to maximizing stakeholder value creation. This nomination follows the notification by Dr. Andrin Oswald, the Company's Chief Executive Officer and Managing Director, that he has resigned from his position in order to focus on his recovery.

On December 20, 2021, the Company announced that Dr. Oswald had taken a medical leave of absence. While Dr. Oswald is on a path to recovery, this will take some additional time, and Dr. Oswald has therefore decided, in consultation and mutual agreement with the Company's supervisory board, to hand over the CEO position to Kim Stratton to ensure continued strong leadership. Dr. Oswald will continue to be available to CENTOGENE as an advisor to ensure a smooth leadership transition.

The transition of the CEO role is effective immediately. Kim Stratton's appointment as a managing director will be formalized at the next shareholder meeting. Kim Stratton has more than 25 years' global commercial expertise in the biopharmaceutical space, with significant experience across multiple geographies, including the U.K., U.S., Europe, and emerging markets.

Most recently, Stratton was CEO of Orphazyme A/S. Stratton also currently serves as a non-executive director on the Boards of Recordati S.p.A, Novozymes A/S, and Vifor Pharma AG.